• Advancement of agentic AI capability in the TrialKey platform
• Execution of commercial contract with Imunexus Therapeutics
• Proposed acquisition of AI-driven semiconductor design company Chipforge

During the March 2026 quarter, Pathkey.AI continued to focus on the development and commercialization of the TrialKey platform, including the advancement of an agentic AI capability known as the TrialKey Criteria Optimiser. This capability introduces a structured, iterative approach to clinical trial design, enabling the generation, evaluation and ranking of protocol alternatives within defined safety, feasibility and design constraints. The company also continued to develop a customer-facing platform to support a transition toward a SaaS-based model, enabling users to build and interrogate machine learning models using TrialKey's dataset. Subsequent to the quarter, Pathkey executed a Services Agreement with Imunexus, representing the largest contract secured to date, with a total potential value of up to A$100,000 plus GST. The company also entered into a binding agreement to acquire 100% of Singapore-based Chipforge Pte Ltd, an AI-driven semiconductor design and verification platform. The proposed acquisition is aligned with Pathkey's strategy of expanding its AI capabilities into complementary, data-intensive industries. During the quarter, the company completed a capital raising of $3.5 million to strengthen its growth and operations.

The company received $197,000 from the disposal of its bitcoin position held via BTX ETF during the quarter. The company had cash of $3.26m as at 31 March 2026 and cash outflows of approximately $230k investing in TrialKey Platform commercialization.

Pathkey.AI is focused on the continued development and commercialization of the TrialKey platform, including the advancement of its agentic AI capabilities. The proposed acquisition of Chipforge is expected to provide significant cross-platform synergies and accelerate development across both platforms.